Recorded Presentation of Optimizing Patient Outcomes - In a Blink of an Eye: Updates in Frontline Therapy with Blinatumomab for Pediatric Acute Lymphoblastic Leukemia

ALL in the pediatric patient demographic has demonstrated a growing improvement in survival rates over the past five decades. However, challenges in management approaches and prognoses persist. The impact of blinatumomab as part of upfront therapy for newly diagnosed standard-risk B-cell ALL is a major milestone in the overall landscape of pediatric ALL. It is important to understand the changes and impacts this has, which may further encourage future research on the role of targeted therapies and the potential to de-intensify the use of conventional standard chemotherapy. 

Target Audience

This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates and other health care professionals who treat patients with cancer.  

Learning Objectives

Following this activity, participants should be able to:

  • Describe the risk-stratified treatment approach for ALL in the pediatric patient population.
  • Summarize the evidence-based literature on blinatumomab in the upfront treatment setting for newly diagnosed patients.
  • Describe future impacts on the treatment of ALL by blinatumomab and other potential targeted therapies.

You may also be interested in

Deploying Novel Therapies for Acute Lymphoblastic Leukemia

Immunotherapies are an important modality in the treatment of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Additional information
Supporters: 

Supported by educational grants from:

  • Johnson & Johnson
  • Genentech, a member of the Roche Group

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
04/30/2026
Course expires: 
04/22/2027
Part of: 
Recorded Presentations from the NCCN 2026 Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology
Fallon Henkel, PharmD
Yale Cancer Center/Smilow Cancer Hospital
 
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions  
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
The faculty listed below has no financial relationships with ineligible companies to disclose.
 
Fallon Henkel, PharmD
 
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-038-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 22, 2027. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing